Investors eye Indonesian pharma market

Global investors are eyeing the Indonesian pharmaceutical market amid growing signs of an increasing shift from potential to actual realities.

The country's expanding middle class and growing and aging population combined with the implementation of a series of new policies like public health insurance are fuelling a rise in demand for healthcare services and pharmaceuticals in particular.

For foreign investors, who will soon be allowed to own 100% of Indonesian companies thanks to a recent rule change, a key driver is the possibility to access Indonesia's 250 million population and other ASEAN countries to which Indonesian exports do not have to pay import duties.